Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 3 · 42.9%High 0 · 0%

Cardiovascular mortality ‐ not measured · patients with stable angina pectoris

The review found no eligible studies for this question.

1 finding from 1 review

Ranolazine for stable angina pectoris 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Non‐cardiovascular mortality ‐ not reported · patients with stable angina pectoris

The review found no eligible studies for this question.

1 finding from 1 review

Ranolazine for stable angina pectoris 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

All‐cause mortality · patients with stable angina pectoris

Ranolazine (add‐on therapy) showed no clear difference in all‐cause mortality compared with placebo (low certainty).

1 finding from 1 review

Ranolazine for stable angina pectoris 2017 · Cochrane Headline outcomes only
RR 0.83 [0.26, 2.71]
3 studies · 2053 participants
Low

Quality of life Scale: 0 to 100. · patients with stable angina pectoris

1 finding from 1 review

Ranolazine for stable angina pectoris 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1563 participants
Moderate

AMI incidence · patients with stable angina pectoris

Ranolazine (add‐on therapy) showed no clear difference in AMI incidence compared with placebo (low certainty).

1 finding from 1 review

Ranolazine for stable angina pectoris 2017 · Cochrane Headline outcomes only
RR 0.4 [0.08, 2.07]
2 studies · 1509 participants
Low

Angina episodes frequency · patients with stable angina pectoris

1 finding from 1 review

Ranolazine for stable angina pectoris 2017 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 2004 participants
Moderate

Adverse events incidence · patients with stable angina pectoris

Ranolazine (add‐on therapy) probably leads to higher adverse events incidence compared with placebo (moderate certainty).

1 finding from 1 review

Ranolazine for stable angina pectoris 2017 · Cochrane Headline outcomes only
RR 1.22 [1.06, 1.4]
3 studies · 2123 participants
Moderate